Allen Institute

Allen Institute, a Seattle-based nonprofit research organization, serves as a prime recipient of federal grants for computational neuroscience, cell-type genomics, brain imaging technology development, and immunology research, with 61% of its recent federal award portfolio composed of prime grants and 39% as a sub-recipient on collaborative research projects. The Institute does not hold federal contracts; all federal work flows through grants from the National Institutes of Health and National Science Foundation.

Allen Institute's customer concentration is heavily weighted toward the NIH research ecosystem. The top five NIH institutes and offices account for 75% of awards by count, led by the National Institute of Mental Health (37 awards), the National Institute of Neurological Disorders and Stroke (25 awards), the National Institute on Aging (17 awards), the National Institute of Allergy and Infectious Diseases (11 awards), and the Office of the Director (10 awards). The National Institute on Drug Abuse anchors the dollars at $22 million combined potential value across four cooperative agreements focused on cellular and transcriptomic responses to substance exposure and infection. Award volume has grown from 13 in 2022 to 23 in 2024 and 2025, with 11 awards in 2026 and 20 awards reaching completion within the next twenty-four months.

Allen Institute's research portfolio spans high-resolution neuroscience infrastructure and cell-type discovery. Representative prime-recipient grants include a $2.225 million collaborative U.S.-Israel project on decision-making neuroscience awarded by NSF SBE (CFDA 47.075, performance through August 2031); a $1.88 million NIMH grant for brainstem cell-type atlas work via single-cell genomics (through December 2028); a $1.385 million NIH Trans-NIH Research Support award for measuring input-output operations of cortical neurons using genetically encoded neurotransmitter indicators (CFDA 93.310, through August 2026); and multiple cooperative agreements on brain connectomics, including a $1.27 million exa-scale tissue readout methods project from the NIH Office of the Director (CFDA 93.310, through September 2027). The Institute also leads the Brain Connects Integrative Connectomics Coordination Center (NINDS, through December 2029) and chairs the Engagement, Outreach, and Coordination Unit for the Brain Initiative Cell Atlas Network (BICAN), serving as hub for multi-institutional standards development and data dissemination across the NIH Brain Initiative portfolio.

As a sub-recipient, Allen Institute contributes specialized capabilities to larger consortia led by Johns Hopkins University, Harvard University, Seattle Children's Hospital, UCSF, UC Irvine, and MIT, performing roles such as electrophysiological recording and circuit analysis, transcriptomic profiling and cell-type characterization, spatial transcriptomics for mapping neuronal projections, immunology service-core assays on multi-omic single-cell platforms, and development of open-source analysis tools and knowledge bases. Sub-awards span neurodevelopmental cell-type mapping, Alzheimer's disease circuit analysis, immunological responses in autoimmunity and infectious disease, and connectomics infrastructure for the broader BRAIN Initiative ecosystem.

The Institute's federal footprint reflects a research-focused mission centered on open-science data generation and tool development for the neuroscience and immunology communities rather than traditional contracting. All customer agencies are components of HHS and NSF. Twenty awards (15% of the prime portfolio) reach ultimate completion in the next twenty-four months, representing recompete opportunity in brain cell-type mapping, connectomics, neural dynamics, and aging-related neuroscience initiatives.